Navigation Links
Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
Date:2/4/2009

GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A.

Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene resulting in a deficiency of factor VIII protein. Lentigen and Expression Therapeutics will develop two types of treatments for Hemophilia: a novel chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder.

"Hemophilia A is a serious disease, affecting about one in 10,000 people worldwide," explained Dr. Boro Dropulic, President and Chief Scientific Officer of Lentigen. "The two therapeutic approaches leverage Lentigen's technology in two important areas: protein expression and cell therapy. Factor VIII is a difficult protein to manufacture but Lentigen's protein expression technology will permit the production of a novel human factor VIII protein at levels highly favorable for commercialization. Secondly, Expression Therapeutics' proprietary factor VIII will be used in a novel stem cell therapy for Hemophilia A that aims to restore the clotting capability of patients suffering from this debilitating disease.

"The platform technology developed by Expression Therapeutics will be used to advance the treatment of hemophilia A. By combining our high expression factor VIII technology with Lentigen's protein expression and gene transfer capabilities, we are confident Lentigen is the ideal partner to help bring this technology to the clinic and marketplace," stated Dr. Trent Spencer, President of Expression Therapeutics.

Tim Ravenscroft, Lentigen's Chief Executive Officer, commented, "We are excited to be working with Expression Therapeutics on factor VIII treatments. The projects are consistent with our strategy of applying Lentigen's technology in diseases of high unmet therapeutic need."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, The University of Pennsylvania, Invitrogen, ThermoFisher Scientific and The U.S. Army. For further information, visit www.lentigen.com.

About Expression Therapeutics

Expression Therapeutics, LLC is a privately owned biotechnology company in Atlanta focused on the development of products that will improve the standard of treatment for individuals with hemophilia A. The high-expression factor VIII technology developed by Expression Therapeutics can be used in the development of both protein replacement and cell therapy-based therapeutics. For further information, visit www.expressiontherapeutics.com

    Lentigen Media Contacts:
    Richard Lewis Communications, Inc. (212) 827-0020
    Gregory Tiberend, gtiberend@rlcinc.com
    Cecelia Heer, cheer@rlcinc.com

    Expression Therapeutics Media Contacts:
    Gabriela Denning, gdenning@expressiontherapeutics.com (678) 278-1140
    Keith Kerstann, kwkerstann@expressiontherapeutics.com


'/>"/>
SOURCE Lentigen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
2. Lentigen Corporation Announces Relocation to New Facility
3. Lentigen Appoints Jim Meade as Vice President of Corporate Development
4. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
7. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
8. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
9. VIRxSYS and Lentigen Announce Litigation Settlement
10. New technique allows simultaneous tracking of gene expression and movement
11. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs ... Insulin Assay from Salimetrics’ SalivaLab , the relationship between insulin and other ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:2/1/2017)... -- IDTechEx Research, a leading provider of independent market ... of a new report, Sensors for Robotics: Technologies, Markets and ... ... ... Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
Breaking Biology News(10 mins):